A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, with or without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer.

IHC analysis of paired biopsies at screening and cycle 1 day 15 showed a trend toward dose-dependent ER degradation for single-agent LSZ102 ( Fig. 2B ), which did not appear to be affected by ribociclib or alpelisib (Supplementary Fig.

also in 53,322 other papers

Degradation of ER was observed in all treatment arms, with an apparent trend suggesting an LSZ102 dose response.

also in 709 other papers